John W. Ostrominski: key facts
- Kind of voice
- Academic
- Role
- MD, MPH, preventive cardiologist and obesity medicine specialist at Brigham and Women's Hospital and Harvard Medical School
- Quoted on
- Elderly care & frailty
- Press citations held
- 2
- Most recently quoted
- 29 Sept 2026
“There are persistent concerns around the balance of risk and benefit with GLP-1 receptor agonist–based medications, such as semaglutide, in this population.”
What John W. Ostrominski has said
“The study findings were consistent with expected clinical event reductions, and the magnitude of quality-of-life improvements was noteworthy... However, decisions to initiate and maintain GLP-1RA-based therapies in persons with frailty should remain individualized.”
MD, MPH, preventive cardiologist and obesity medicine specialist at Brigham and Women's Hospital and Harvard Medical School · Elderly care & frailty · 29 Sept 2026 · Semaglutide Found to Benefit Frail Patients ↗
Where John W. Ostrominski has been quoted
- GLP-1s Could Help Older Adults With Frailtyeverydayhealth.com · 29 Sept 2026
- Semaglutide Found to Benefit Frail Patientsmedscape.com · 29 Sept 2026
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 29 Sept 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.